Skip to content
Screener

Bicara Therapeutics BCAX Q1 2025 earnings

Reported May 13, 2025 · Before market open

EPS-$0.68Miss by $0.28
EPS estimate-$0.40

Next report

Aug 11, 2026 (Tomorrow)
EPS estimate-$0.82

Financials

Q1 2025

Income statement

See full
Operating income-$41.8M-172%
Net income-$36.8M-195%
EPS (diluted)-$0.68+96.4%

Balance sheet

See full
Cash & equivalents$462.1M+114%
Total debt$591.0K—
Total equity$459.0M+387%
Total assets$478.1M—

Cash flow

See full
Operating cash flow-$28.1M-92.7%
CapEx--100%
Free cash flow-$28.1M-92.6%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$710.44M—
Enterprise value$248.96M—

Returns & leverage

See full
Debt / equity0×—
Current ratio24.6×—

FAQ

When did Bicara Therapeutics report Q1 2025 earnings?
Bicara Therapeutics (BCAX) reported Q1 2025 earnings on May 13, 2025 before market open.
What were Bicara Therapeutics's Q1 2025 revenue and EPS?
Bicara Therapeutics reported eps of $-0.68 for Q1 2025.
Did Bicara Therapeutics beat estimates in Q1 2025?
EPS missed the consensus estimate of $-0.40 by $0.28.
How did Bicara Therapeutics's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 149.3% from $-0.27.
Where can I find Bicara Therapeutics's Q1 2025 SEC filings?
You can read the 8-K earnings release (0002023658-25-000034) and the 10-Q periodic report (0002023658-25-000039) directly on SEC EDGAR. The filing index links above go to sec.gov.